Discontinued — last reported Q1 '17
An increase suggests higher investment in corporate-level infrastructure or intangible assets, while a decrease may indicate reduced capital intensity at the corporate level.
This represents the non-cash expenses allocated to the reconciling segment, primarily reflecting the systematic allocati...
Commonly reported by large pharmaceutical firms as 'Corporate' or 'Unallocated' depreciation and amortization.
zts_segment_material_reconciling_items_depreciation_depletion_and_amortization